All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Glofit-GemOx vs R-GemOx for R/R DLBCL: Results from the STARGLO trial
Bookmark this article
|
Results from the phase III STARGLO trial (NCT04408638) of glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) vs rituximab plus gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) were presented at the European Hematology Association (EHA) 2024 Hybrid Congress by Abramson.1 |
| Key learnings: |
|
The primary endpoint of overall survival (OS) was met. |
|
After a median follow-up of 20.7 months, median OS was 25.5 months vs 12.9 months in the Glofit-GemOx and R-GemOx arms, respectively (hazard ratio [HR], 0.62; p = 0.006). |
|
Glofit-GemOx was associated with improved progression-free survival (PFS) and a higher complete response (CR) rate vs R-GemOx: median PFS was 13.8 months vs 3.6 months (HR, 0.40; p < 0.000001) and the CR rates were 58.5% vs 25.3% (p < 0.0001), respectively. |
|
The safety profile of Glofit-GemOx was consistent with that of the individual agents. |
|
Glofitamab is the first CD20xCD3 bispecific antibody to demonstrate a survival benefit in DLBCL in a randomized phase III trial. |
| The efficacy data from the phase III STARGLO trial and the tolerable safety profile of Glofit-GemOx supports the use of Glofit-GemOx in the treatment of patients with R/R DLBCL. |
- Abramson J. Glofitamab plus gemcitabine and oxaliplatin (GLOFIT-GemOx) for relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL): results of a global randomized phase III trial (STARGLO). Abstract #LB3438. Presented at: European Hematology Association 2024 Hybrid Congress; Jun 13–16; Madrid, ES.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
60 votes - 45 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox